To provide a composition capable of indirectly inducing osteogenesis by suppressing differentiation into osteoclasts and/or promoting differentiation into osteoblasts. A composition for use in suppressing differentiation into osteoclasts and/or promoting differentiation into osteoblasts according to the present disclosure includes proliferative megakaryocytes and/or mature megakaryocytes.
The purpose of the present invention is to provide a bone-forming composition comprising enlarged megakaryocytes and/or extracellular secretions derived from enlarged megakaryocytes. The bone-forming composition according to the present disclosure comprises enlarged megakaryocytes and/or extracellular secretions derived from enlarged megakaryocytes.
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
3.
METHOD FOR PRODUCING MULTINUCLEATED MEGAKARYOCYTE WITH ENHANCED PLATELET PRODUCTION CAPABILITY, METHOD FOR PRODUCING PLATELETS, METHOD FOR PRODUCING PLATELET PREPARATION, AND METHOD FOR PRODUCING BLOOD PREPARATION
A method for improving the amount of platelets produced. The production method is a method for producing multinucleated megakaryocyte cells with enhanced platelet production capability, the method including a multinucleation step of inducing multinucleated megakaryocyte cells through multinucleation of pre-multinucleated megakaryocyte cells in the presence of a growth factor of the pre-multinucleated megakaryocyte cells. In the multinucleation step, the multinucleated megakaryocyte cells are induced by suppressing the activity of at least one protein selected from the group consisting of an aryl hydrocarbon receptor (AhR), a Rho-associated kinase (ROCK), dual-specificity tyrosine phosphorylation-regulated kinases (DYRK), and myosin 2, and multinucleating the pre-multinucleated megakaryocyte cells in the presence of harmine.
Healthy functional platelets are mass produced. A method for producing platelets, comprising: (1) a culture step of culturing megakaryocytes in a platelet producing medium in the presence of mechanical stress and platelet production promoting factors including MIF, NRDc, IGFBP2, TSP-1, PAI-1, and CCL5, and (2) a harvest step of harvesting the platelets obtained by the culture step; wherein the culture step comprises: (a) a step of promoting a release of the platelet production promoting factors from megakaryocytes by mechanical stress; and/or (b) a step of externally adding platelet production promoting factors including MIF, NRDc, and IGFBP2.
A composition having cell-derived physiological activity is provided. An osteogenic composition includes a treated product obtained by treating megakaryocytes or treating a culture thereof.
[Problem] Conventionally, it has been known that the production efficiency of platelets can be optimized by agitating contents under the agitation condition that the shear force index is a predetermined value. By utilizing this, the present invention is to optimize the production efficiency of platelets further by using a maximum speed and an actual mean speed when blades move. [Solution] The present invention is characterized in that: an agitation device comprises an agitation container in which contents for producing platelets are contained, an agitation means for agitating the contents in the agitation container by rotation or reciprocating movement, and a control device which includes a storage unit and a calculation unit and which controls the rotation or reciprocating movement of the agitation means; and a method comprises a first step for obtaining a set maximum speed determination function indicating the relationship between the set maximum speed of the agitation means and a shear force index, a second step for obtaining the set maximum speed from a value of the desired shear force index by using the set maximum speed determination function, and a third step for agitating contents in the agitation container on the basis of the set maximum speed.
C12M 1/02 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens d'agitationAppareillage pour l'enzymologie ou la microbiologie avec des moyens d'échange de chaleur
B01F 27/93 - Mélangeurs à agitateurs tournant dans des récipients fixesPétrins avec des agitateurs tournant autour d'un axe sensiblement vertical avec des disques rotatifs
B01F 33/25 - Mélangeurs avec des éléments de mélange en vrac, p. ex. des boules en vrac dans un récipient
A composition having cell-derived physiological activity is provided. The composition according to the present invention contains a treated product of megakaryocytes or a culture of the megakaryocytes.
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C12N 5/078 - Cellules du sang ou du système immunitaire
8.
METHOD FOR PRODUCING MULTINUCLEATED MEGAKARYOCYTE WITH ENHANCED PLATELET PRODUCTION CAPABILITY, METHOD FOR PRODUCING PLATELETS, METHOD FOR PRODUCING PLATELET PREPARATION, AND METHOD FOR PRODUCING BLOOD PREPARATION
The present invention addresses the problem of providing a method that is capable of improving platelet production. This production method is for producing a multinucleated megakaryocyte with an enhanced platelet production capability, the method comprising a multinucleation step in which, in the presence of a growth factor of a megakaryocyte before multinucleation, a megakaryocyte before multinucleation is multinucleated to induce a multinucleated megakaryocyte. In the multinucleation step, the activity of at least one selected from the group consisting of an aromatic hydrocarbon receptor (AhR), Rho-binding kinase (ROCK), a bispecific tyrosine-phosphorylation regulated kinase (DYRK), and myosin 2 is suppressed, and in the presence of harmine, the megakaryocyte before multinucleation is multinucleated to induce a multinucleated megakaryocyte.
An object of the present invention is to provide a novel preservation solution for preserving mammalian cells over a long period of time in a non-frozen state. Ascorbic acid and/or niacin is added to an isotonic solution to prepare a preservation solution. The preservation solution is mixed with platelets and preserved under shaking. Decrease in the functions and viability of the platelets can thereby be suppressed for at least 10 days. Alternatively, the aforementioned preservation solution is mixed with mesenchymal stem cells, megakaryocytes, or T cells and preserved in a non-frozen state. Decrease in the functions and viability of these cells can thereby be suppressed for at least several days to several tens of days.
Provided is a composition having a cell-derived physiological activity. The osteogenic composition according to the present invention contains a processed product of megakaryocytes or a culture thereof.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C12N 15/12 - Gènes codant pour des protéines animales
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
11.
Method for screening for platelet production promoters
The present invention provides a method for screening for platelet production promoters, the method including a step for selecting a candidate substance that significantly increases expression of TUBB1 as a platelet production promoter.
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12Q 1/6897 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques faisant intervenir des gènes rapporteurs liés de façon fonctionnelle à des promoteurs
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
12.
Method for producing culture containing megakaryocytes, and method for producing platelets using same
The present invention provides a method for producing megakaryocytes that have an increased capacity to produce platelets, the method comprising a step of culturing, under conditions that cause the death of cells that do not express a gene that is specifically expressed by megakaryocytes, cells that have the capacity to differentiate into megakaryocytes.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 5/078 - Cellules du sang ou du système immunitaire
Provided is a composition having cell-derived physiological activity. The composition according to the present invention includes a processed product of megakaryocytes or a cultured product thereof.
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 17/02 - Médicaments pour le traitement des troubles dermatologiques pour traiter les blessures, les ulcères, les brûlures, les cicatrices, les cheloïdes, ou similaires
A61P 17/14 - Médicaments pour le traitement des troubles dermatologiques pour le traitement de la calvitie ou de l'alopécie
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 19/04 - Médicaments pour le traitement des troubles du squelette des troubles non-spécifiques du tissu conjonctif
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
Methods of production and apparatuses for production for stably producing healthy and functional platelets, and methods for determining operating conditions of an apparatus for producing platelets are provided. The present invention relates to methods of production comprising a step of culturing megakaryocytes in a platelet production medium C, wherein the step of culturing comprises a step of stirring a medium C in containers 1, 4 using stirring mechanisms 2, 5. In one method of production, the step of stirring comprises reciprocating stirring blades 21, 24 in the stirring mechanisms 2, 24 such that any of predetermined turbulent energy, shearing stresses, or Kolmogorov scale is produced, in the medium C. In another method of production, the step of stirring comprises pivoting a stirring blade 51 in the stirring mechanism 5 wherein a plurality of stationary members 53 is placed therearound in a bottom region 4e of the container 4 such that the step of stirring produces turbulence in the medium C. The present invention also relates to apparatuses for production for carrying out the method of production. The present invention also relates to a method for determining operating conditions of an apparatus for producing platelets.
The present invention provides a megakaryocyte progenitor cell and a megakaryocytic cell, and a method for producing the same. Specifically, the present invention provides: a megakaryocyte progenitor cell or a megakaryocytic cell containing papillomavirus E6 genes and/or E7 genes; and a method for producing the same.
A cell suspension treatment system is provided with a circulation circuit and a filling liquid supply source which supplies a filling liquid to the circulation circuit. The circulation circuit comprises a hollow fiber membrane filter, a reservoir, a pump which is disposed on the downstream side, in the circulation direction, of the reservoir and on the upstream side of the hollow fiber membrane filter, and a valve which is disposed on the downstream side of the reservoir and on the upstream side of the pump. The filling liquid supply source is connected to a part of the circulation circuit between the valve and the pump. After a concentrated cell suspension is reserved in the reservoir, the filling liquid supply source starts to supply the filling liquid to the circulation circuit in the state where the valve is closed and the pump is driven. Thus, the filling liquid forces the cell suspension, which remains in a part of the circulation circuit to the inlet port of the reservoir, to flow toward the reservoir.
C12M 3/06 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus avec des moyens de filtration, d'ultrafiltration, d'osmose inverse ou de dialyse
The present invention addresses the problem of providing a novel storage liquid for storing mammalian cells over a long period of time in a non-frozen state. Ascorbic acid and/or niacin are added to an isotonic liquid to give a storage liquid. Then the storage liquid is mixed with platelets and stored under shaking. Thus, deterioration in the functions of the platelets and a decrease in the survival rate thereof can be prevented for at least 10 days. When the aforesaid storage liquid is mixed with mesenchymal stem cells, megakaryocytes or T cells and stored in a non-frozen state, deterioration in the functions of these cells and a decrease in the survival rate thereof can be prevented for at least from several days to several ten days.
C12N 5/078 - Cellules du sang ou du système immunitaire
C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
C12N 1/04 - Conservation des micro-organismes à l'état viable
18.
METHOD FOR PRODUCING CYTOPENIA MODEL ANIMAL, CYTOPENIA MODEL ANIMAL, METHOD FOR EVALUATING BLOOD CELL FUNCTION, METHOD FOR PRODUCING BLOOD CELLS, METHOD FOR SCREENING CYTOPENIA THERAPEUTIC DRUG MATERIAL CANDIDATE, AND METHOD FOR PRODUCING CYTOPENIA THERAPEUTIC DRUG MATERIAL CANDIDATE
Provided is a method for producing a cytopenia model animal having a lower blood cell count than an X-ray irradiation-induced cytopenia model animal. This method for producing a cytopenia model animal comprises: an irradiation step for irradiating a non-human animal with radiation; and an administration step for administering an anti-blood cell antibody to the non-human animal.
G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/86 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir le temps de coagulation du sang
Healthy functional platelets are mass produced. A method for producing platelets, comprising: (1) a culture step of culturing megakaryocytes in a platelet producing medium in the presence of mechanical stress and platelet production promoting factors including MIF, NRDc, IGFBP2, TSP-1, PAI-1, and CCL5, and (2) a harvest step of harvesting the platelets obtained by the culture step; wherein the culture step comprises: (a) a step of promoting a release of the platelet production promoting factors from megakaryocytes by mechanical stress; and/or (b) a step of externally adding platelet production promoting factors including MIF, NRDc, and IGFBP2.
The present invention provides a method for producing platelets that can improve at least one of the ability of megakaryocyte to produce platelets and the bioactivity of platelets produced even in high-density culture, for example. The method for producing platelets of the present invention includes a platelet producing step of producing platelets from megakaryocytes, wherein the platelet producing step is performed in the presence of at least one of glycine and cysteine.
Provided is a method for producing platelets, in which damage to platelets is suppressed compared with a method in which platelets are separated using a filter from a megakaryocyte culture, and then the platelets are concentrated using a hollow fiber membrane and are further washed using the hollow fiber membrane, and purified platelets can be produced in a shorter period of time compared with the time that is taken to perform the above-described method so as to reduce damage to platelets. The method for producing purified platelets of the present invention includes a concentrating step of concentrating a megakaryocyte culture, and a centrifuging step of centrifuging platelets from an obtained concentrate.
The present invention provides a method for culturing pluripotent stem cells, comprising the step of contacting pluripotent stem cells with laminin 421 or a fragment thereof, laminin 121 or a fragment thereof, or a combination thereof.
Provided is a platelet production method with which production of platelets from megakaryocytes and/or the bioactivity of the produced platelets can be increased, even, for example, when cultured at a high density. The platelet production method according to the present invention is characterized by including a platelet production step for producing platelets from megakaryocytes and carrying out said platelet production step in the presence of at least one of glycine and cysteine.
Provided is a method for manufacturing blood platelets that involves less damage to the blood platelets than a method in which the blood platelets are separated from a megakaryocyte culture with a filter and thereafter are concentrated using a hollow fiber membrane and washed using a hollow fiber membrane, and that can be executed in a shorter time than it takes to execute the abovementioned method so that damage to the blood platelets would be reduced. This method for manufacturing purified blood platelets is characterized by including a concentration step in which a megakaryocyte culture is concentrated and a centrifugal separation step in which the blood platelets are centrifugally separated from the obtained concentrate.
Provided is a method for inducing mesoderm, comprising a step of bringing pluripotent stem cells into contact with bone morphogenetic protein 4 (BMP4) or CHIR for at least 3 days.
A61K 35/28 - Moelle osseuseCellules souches hématopoïétiquesCellules souches mésenchymateuses de toutes origines, p. ex. cellules souches dérivées de tissu adipeux
C12N 5/078 - Cellules du sang ou du système immunitaire
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
A61P 7/08 - Substitut de plasmaSolutions de perfusionDyalisats ou hémodyalisatsMédicaments pour le traitement des troubles électrolytiques ou acido-basiques, p. ex. choc hypovolémique
A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
The present invention provides a highly functional platelet production promoting agent which comprises one or a plurality of aryl hydrocarbon receptor (AhR) antagonists and one or a plurality of Rho-associated coiled-coil forming kinase (ROCK) inhibitors.
C12N 5/078 - Cellules du sang ou du système immunitaire
A61K 31/553 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. loxapine, staurosporine
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p. ex. clozapine, dilazèpe
C12N 5/077 - Cellules mésenchymateuses, p. ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
The present invention provides: a platelet production promoter that contains one or more substances selected from the group consisting of Wnt inhibitors and FMS-like tyrosine kinase (FLT) inhibitors; and a platelet production method that uses this platelet production promoter.
C12N 5/078 - Cellules du sang ou du système immunitaire
A61P 7/04 - AntihémorragiquesProfacteurs de coagulationAgents hémostatiquesAgents antifibrinolytiques
A61K 31/444 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p. ex. amrinone
A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
The present invention provides a method for screening for platelet production promoters, the method including a step for selecting a candidate substance that significantly increases expression of TUBB1 as a platelet production promoter.
C12Q 1/6897 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques faisant intervenir des gènes rapporteurs liés de façon fonctionnelle à des promoteurs
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
29.
PLATELET PRODUCTION METHOD AND APPARATUS AND METHOD FOR DETERMINING OPERATING CONDITIONS IN PLATELET PRODUCTION APPARATUS
Provided are a method and an apparatus for stably producing sound and functional platelets and a method for determining operating conditions in the platelet production apparatus. The present invention relates to a production method including a step for culturing megakaryocyte cells in a platelet production medium C, wherein the culturing step includes a step for stirring the medium C in containers 1, 4 by using stirring mechanisms 2, 5. In one production method, the stirring step involves reciprocating agitating blades 21, 24 of the stirring mechanism 2 so as to generate a predetermined turbulent flow energy, a shear stress, or a Kolmogorov scale in the medium C. In another production method, the stirring step involves rotating a stirring blade 51 of the stirring mechanism 5 in a state in which a plurality of stationary members 53 is arranged therearound in a bottom region 4e of the container 4 so that a turbulent flow is generated in the medium C. The present invention also relates to a production apparatus for carrying out the production method. The present invention also relates to a method for determining operating conditions in the platelet production apparatus.
C12N 5/078 - Cellules du sang ou du système immunitaire
B01F 7/16 - Mélangeurs à agitateurs tournant dans des récipients fixes; Pétrins avec agitateurs tournant autour d'un axe vertical
B01F 7/18 - Mélangeurs à agitateurs tournant dans des récipients fixes; Pétrins avec agitateurs tournant autour d'un axe vertical à pales ou à bras
B01F 11/00 - Mélangeurs avec mécanismes à secousses, oscillants ou vibrants
C12M 1/02 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens d'agitationAppareillage pour l'enzymologie ou la microbiologie avec des moyens d'échange de chaleur
C12M 3/00 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
30.
Method for producing platelets using reciprocating stirring device
The present invention provides a method for producing platelets, including the step of culturing megakaryocyte cells in a culture solution in a culture vessel, wherein in the culturing step, the culture solution is stirred by a stirring blade moving reciprocally.
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
C12M 1/02 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens d'agitationAppareillage pour l'enzymologie ou la microbiologie avec des moyens d'échange de chaleur
C12M 1/36 - Appareillage pour l'enzymologie ou la microbiologie comportant une commande sensible au temps ou aux conditions du milieu, p. ex. fermenteurs commandés automatiquement
C12M 3/08 - Appareils pour la désagrégation des tissus
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
The present invention provides a method for producing purified platelets from a culture of megakaryocytes, comprising a first centrifugal separation step of centrifugally separating the culture at a centrifugal force of 150×g to 550×g, and a second centrifugal separation step of centrifugally separating, at a centrifugal force of 600×g to 4000×g, a liquid component recovered in the first centrifugal separation step.
The present invention provides a method for producing platelets, and the method comprises a step of culturing megakaryocytes in a culture solution in a culture vessel, wherein the culture solution is stirred with a stirrer in the culture step.
To produce a large quantity of healthy, functional platelets. A method for producing platelets that includes (1) a culture step for culturing megakaryocyte cells in platelet production medium in the presence of physical stimulation and platelet-production-promoting factors including MIF, NRDc, IGFBP2, TSP-1, PAI-1, and CCL5, and (2) a recovery step for recovering platelets obtained in the culture step, wherein the culture step includes: (a) a step for promoting the release of platelet-production-promoting factors from the megakaryocyte cells by physical stimulation; and/or (b) a step for adding platelet-production-promoting factors including MIF, NRDc, and IGFBP2 from outside.
The present invention identifies heterogeneity in megakaryocytic cell groups and classifies cell groups. A method for identifying heterogeneity in cells in megakaryocytic cell groups. The method includes the following steps. (1) A step for introducing mRNA into megakaryocytic cell groups, the mRNA including: a nucleic acid sequence that is specifically recognized by microRNA; and a functionally linked marker gene. (2) A step for using the translated amount of the marker gene as an indicator to identify cell groups that have different characteristics.
C12Q 1/04 - Détermination de la présence ou du type de micro-organismeEmploi de milieux sélectifs pour tester des antibiotiques ou des bactéricidesCompositions à cet effet contenant un indicateur chimique
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
35.
METHOD FOR CULTURING PLURIPOTENT STEM CELL ON SPECIFIC LAMININ
The present invention provides a method for culturing a pluripotent stem cell, said method comprising the step of bringing the pluripotent stem cell into contact with laminin 421 or a fragment thereof, or laminin 121 or a fragment thereof, or a combination thereof.
C12N 5/071 - Cellules ou tissus de vertébrés, p. ex. cellules humaines ou tissus humains
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Pharmaceutical preparations (excluding agricultural chemicals); hemotoropic agents; blood substitutes; hemostatics; blood products; blood for medical use; cells for medical or clinical use; test paper for medical use. Laboratory apparatus and instruments; laboratory experiment apparatus and instruments for collecting and processing of blood. Medical apparatus and instruments; blood testing apparatus and instruments. Testing, inspection or research of pharmaceuticals, cosmetics or foodstuffs; testing, inspection or research of treatment methods and techniques for medical care; research and development in the field of cytology; blood analysis for scientific purposes; research and development of blood products, blood for medical use and hemotoropic agents. Blood tests and analysis; providing information of blood tests; providing medical information; rental of medical apparatus and instruments.
37.
MESODERM INDUCTION METHOD HAVING HIGH BLOOD CELL DIFFERENTIATION CAPACITY
The present invention provides a mesoderm induction method including a step for bringing pluripotent stem cells and bone morphogenetic protein 4 (BMP4) or CHIR into contact for three days or longer.
A61P 7/08 - Substitut de plasmaSolutions de perfusionDyalisats ou hémodyalisatsMédicaments pour le traitement des troubles électrolytiques ou acido-basiques, p. ex. choc hypovolémique
C12N 5/078 - Cellules du sang ou du système immunitaire
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p. ex. cellules transformées par des virus
A screening method of a platelet production promoter is provided which involves a step in which a candidate substance that significantly increases the expression of TUBB1 is selected as a platelet production promoter.
C12N 5/078 - Cellules du sang ou du système immunitaire
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
39.
PLATELET PRODUCTION PROMOTER AND METHOD OF PRODUCING PLATELETS USING SAME
A platelet production promoter which contains one or multiple substances selected from a group consisting of Wnt inhibitors and FMS-like tyrosine kinase (FLT) inhibitors, and a method of producing platelets which uses said platelet production promoter, are provided.
The present invention provides a method for preparing platelets, the method comprising a step for culturing megakaryocytic cells in a culture solution within a culture vessel, wherein, at said culturing step, the culture solution is stirred by a stirring blade moving reciprocally.
The present invention provides a method for producing purified platelets from a megakaryocyte culture, said method including a first centrifugation step in which the culture is centrifuged at a centrifugal force of 150×g to 550×g, and a second centrifugation step in which a liquid component collected in the first centrifugation step is centrifuged at a centrifugal force of 600×g to 4,000×g.
The present invention provides a production method for platelets, including a step in which megakaryocytic cells are cultured in a culture solution inside a culture vessel. The culture solution is agitated using an agitator in said culturing step.
The present invention provides a high-performance platelet production enhancer that includes one or multiple aryl hydrocarbon receptor (AhR) antagonists and one or multiple Rho-associated coiled-coil forming kinase (ROCK) inhibitors.
The present invention is a method for producing stem cell clones, wherein the method includes (i) a step for introducing into stem cells an exogenous gene associated with induction of differentiation into somatic cells, (ii) a step for inducing the stem cells into which the exogenous gene was introduced to differentiate into somatic cells, (iii) a step for dedifferentiating the somatic cells that have been induced to differentiate, and (iv) a step for isolating stem cells incorporating the exogenous gene into the chromosome from the stem cell colony formed in step (iii).
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
The present invention provides a method for producing megakaryocytes having increased platelet productivity, and the method includes a step for culturing cells having differentiation potency toward megakaryocytes, under a condition in which cells not expressing a gene expressed specifically in megakaryocytes undergo cell death.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Blood components; blood for medical purposes; hemotropic agents. Testing, inspection and research services in the field of pharmaceuticals; testing, inspection and research services in the field of methods and technologies of medical treatment; research and development services in the field of cytology; blood analysis services; research and development services in the field of blood products, blood for medical purposes and hemotropic agents.
A composition for maintaining a function of platelets, the composition comprising, as an active ingredient, a compound represented by the following general formula (I) or a salt thereof, or a solvate thereof:
Z represents any one of a hydrogen atom and a C1 to C6 alkyl group.
C07D 295/135 - Composés hétérocycliques contenant des cycles polyméthylène imine d'au moins cinq chaînons, des cycles aza-3 bicyclo [3.2.2] nonane, piperazine, morpholine ou thiomorpholine, ne comportant que des atomes d'hydrogène liés directement aux atomes de carbone du cycle avec des radicaux hydrocarbonés substitués liés aux atomes d'azote du cycle substitués par des atomes d'azote liés par des liaisons simples ou doubles avec les atomes d'azote du cycle et les atomes d'azote substituants séparés par des carbocycles ou par des chaînes carbonées interrompues par des carbocycles
C07C 317/28 - SulfonesSulfoxydes ayant des groupes sulfone ou sulfoxyde et des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso, liés au même squelette carboné avec des groupes sulfone ou sulfoxyde liés à des atomes de carbone acycliques du squelette carboné
C12N 5/078 - Cellules du sang ou du système immunitaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
48.
N-hydroxyformamide derivative and medicament containing same
A compound represented by the following general formula (I) which has ADAM17 inhibitory activity, or a salt thereof, or a solvate thereof:
5 represents a hydrogen atom or a C1-C6 alkyl group or the like; m indicates an integer of from 0 to 4; and Z represents a hydrogen atom or a C1-C6 alkyl group.
A01N 41/12 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de soufre lié à un hétéro-atome ne comportant pas de liaison soufre-oxygène, p. ex. polysulfures
The present invention addresses the problem of providing a novel storage liquid for storing mammalian cells over a long period of time in a non-frozen state. Ascorbic acid and/or niacin are added to an isotonic liquid to give a storage liquid. Then the storage liquid is mixed with platelets and stored under shaking. Thus, deterioration in the functions of the platelets and a decrease in the survival rate thereof can be prevented for at least 10 days. When the aforesaid storage liquid is mixed with mesenchymal stem cells, megakaryocytes or T cells and stored in a non-frozen state, deterioration in the functions of these cells and a decrease in the survival rate thereof can be prevented for at least from several days to several ten days.
